Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma

The outcome in esophageal adenocarcinoma (EAC) is still poor with only 20% of patients in Western populations surviving for more than 5 years. Almost nothing is known about the precise composition of immune cells and their gene expression profiles in primary resected EACs and also nothing compared t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagener-Ryczek, Svenja, Schoemmel, Max, Kraemer, Max, Bruns, Christiane, Schroeder, Wolfgang, Zander, Thomas, Gebauer, Florian, Alakus, Hakan, Merkelbach-Bruse, Sabine, Buettner, Reinhard, Loeser, Heike, Thelen, Martin, Schlößer, Hans A., Quaas, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113210/
https://www.ncbi.nlm.nih.gov/pubmed/31960110
http://dx.doi.org/10.1007/s00262-019-02475-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113210/
https://www.ncbi.nlm.nih.gov/pubmed/31960110
http://dx.doi.org/10.1007/s00262-019-02475-w

Ejemplares similares